COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,032 Articles (22,627 medRxiv, 8,405 bioRxiv)

Most recent first Previous |  Page 48: Articles 471-480  | Next

A nasal vaccine candidate, based on S2 and N proteins from SARS-CoV-2, generates a broad antibody response systemic and at lower respiratory tract.
Lobaina, Y., Chen, R., Vazquez-Blomquist, D., Suzarte, E., Zhang, M., Zhou, Z., Lan, Y., Guillen, G., Li, W., Perera, Y., Hermida, L.
10.1101/2025.05.09.653001 — Posted: 2025-05-09
The impact of COVID-19 infection experience on risk perception and preventive behaviour: A cohort study
Murakami, M., Yamagata, M., Miura, A.
10.1101/2025.05.07.25327146 — Posted: 2025-05-08
Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV
Rana, M., Haydel, B., Carrara, G., Gleason, C., Mauldin, J., Srivastava_, K., Florman, S., Aberg, J., Van Kesteren, M., Mischka, J., Carreno, J. M., Singh, G., Mendu, D. R., STUDY GROUP, , Wajnberg, A., Cordon-Cardo, C., Krammer, F., Simon, V.
10.1101/2025.05.07.25327192 — Posted: 2025-05-08
Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study
Tsang, T., Sullivan, S., Huang, X. J., Wang, C., Peng, L., Yang, B., Cowling, B. J.
10.1101/2025.05.08.25327221 — Posted: 2025-05-08
Long COVID and Work in the UK: Challenges, Support and Perspectives
Wei, H., Daniels, S., Wiggans, R., Coleman, A., Bramwell, D., McElvenny, D., Forde, D., van Tongeren, M.
10.1101/2025.05.08.25327220 — Posted: 2025-05-08
Multi-step antibody class switching in a primary human response is restricted after IGHG2 and dependent on B cell maturation stage.
Garcia, G. M., Ng, J. C., Stewart, A. T., Sinclair, E., Blair, P., Kateregga, D., Gander, A., Kipling, D., Guo, D., Servius, L., Piper, C., Baig, Z., Fraternali, F., Mauri, C., Dunn-Walters, D.
10.1101/2025.05.07.652638 — Posted: 2025-05-08
No Evidence of Direct Activation of Human Neutrophil Responses by Multivalent Prefusion Trimeric SARS-CoV-2 Spike Protein ex vivo
Fortin, A., Huot, S., Caron, E., Laflamme, C., Pagliuzza, A., Chomont, N., Gilbert, C., Zhang, B., Kwong, P. D., Pouliot, M., Grandvaux, N.
10.1101/2025.05.08.652856 — Posted: 2025-05-08
Beyond Natural Antibodies: Scaffold-Based Generation of Novel Anti-3CLpro Nanobody Nb01
Zhan, Z., Luo, C., Xiong, J., Jiang, Y., Li, Y., Huang, F., Cai, Y., Liu, J.
10.1101/2025.05.06.652338 — Posted: 2025-05-07
Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric Warhead
Veeck, C., Laube, L., Werner, A. D., Diederich, W., Becker, S.
10.1101/2025.05.03.652023 — Posted: 2025-05-07
Number of Austrian SARS-CoV-2 infections in the 2024/2025 season: Analysis of national wastewater data
Riedmann, U., Rauch, W., Schenk, H., Oberacher, H., Ioannidis, J., Pilz, S.
10.1101/2025.05.05.25327005 — Posted: 2025-05-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).